| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 17.3 | 13.9 | 0.0 |
| Total income | 17.3 | 13.9 | 0.0 |
| Profit before exceptional items & tax | 3.5 | 1.9 | 0.0 |
| Profit before tax | 3.5 | 1.9 | 0.0 |
| Net profit | 2.8 | 1.4 | 0.0 |
| Operating margin | 20.2% | 13.7% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +100.00% |
|---|
Source
Read the filing ↗
BSE results filing, BSE: 544759. Figures extracted from the filing.
Goldline Pharmaceutical Ltd: key numbers
- Share price
- ₹32.49
- Market cap
- ₹31.19 Cr
- Revenue (annual)
- ₹31.20 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.6×Sector 50.4×
- Promoter holding
- 57.29%
- FII holding
- 5.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.